<DOC>
	<DOCNO>NCT02270489</DOCNO>
	<brief_summary>This randomize controlled parallel Group phase I study investigate safety immunological/ therapeutic activity two new vaccine , AFFITOPE® PD01A AFFITOPE® PD03A , give patient early Multiple System Atrophy ( MSA ) . In total 30 patient plan enrol study : 12 patient treatment arm receive either 75µg AFFITOPE® PD01A ( adjuvant ) 75µg AFFITOPE® PD03A ( adjuvant ) 6 patient control group receive reference substance ( Placebo ) . Over study duration 52 week , study participant receive 4 injection basic immunization 4-weekly interval 1 boost immunization 36 week first injection . Male female patient age 30 75 year participate trial . 2 study site France ( Bordeaux Toulouse ) involve . AFF009 part project SYMPATH fund European Commission ( FP7-HEALTH-2013-INNOVATION-1 project ; N° HEALTH-F4-2013-602999 ) .</brief_summary>
	<brief_title>Study Assessing Safety Therapeutic Activity AFFITOPE® PD01A PD03A Patients With Early MSA</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<criteria>Possible probably MSA diagnosis ( MSAP MSAC ) accord Gilman 2008 consensus criterion Onset MSA symptoms less 4 year Participants anticipate survival least 3 year opinion PI Written inform consent obtain prior study entry MSA patient &gt; 30 &lt; 75 year age time study entry Female patient childbearing potential use medically accept contraceptive method Stable medication MSA symptom ( Levodopa , Dopamine agonists , Midodrine , Fludrocortisone , monoamine oxidaseB CatecholOmethyltransferase inhibitor ; Antidepressants , Laxatives , NSAIDs paracetamol basic medication pain musculoskeletal system ) Pregnant lactate woman Sexually active woman childbearing potential use medically accept birth control method Patients dementia ( MOCA Screening &lt; 21 ) Speech impairment assess score ≥ 3 UMSARS question 1 Swallowing impairment assess score ≥ 3 UMSARS question 2 Impairment ambulation assess score ≥ 3 UMSARS question 7 History evidence central nervous system disorder like stroke , angioma relevant neurological disease History malignancy skin cancer last 5 year ( consider cure , patient might include ) Active passive vaccination 4 week first vaccination Day 0 main study period end Day 280 . Emergency vaccination acceptable Use investigational nonregistered drug vaccine addition study vaccine entire study period Subjects participate participate another interventional clinical trial within 60 day prior baseline Blood donation within 4 week prior first vaccination . History autoimmune disease , severe hypersensitivity reaction anaphylaxis , allergic bronchial asthma severe allergic rhinoconjunctivitis Known hypersensitivity allergic reaction one component vaccine A family history congenital hereditary immunodeficiency Administration chronic ( defined 14 day ) immunosuppressant immunemodifying drug within six month first vaccination entire study period . For corticosteroid like prednisone equivalent ≥ 0.05 mg/kg/day . Topical inhale steroid allow Intake non steroidal antiinflammatory drug ( NSAIDs ) paracetamol basic medication pain musculoskeletal system within three day prior vaccination AFFITOPE® PD01A AFFITOPE® PD03A Placebo If patient show acute febrile infection ( ≥ 37.8° Celsius ) day vaccination , administration Investigational Medicinal Product ( IMP ) postpone resolution infection Infection human immunodeficiency virus ( HIV , negative test result within 30 day screen acceptable ) , Hepatitis B ( HBsAg ) Hepatitis C Significant systemic illness ( e.g . chronic renal failure , chronic liver disease , poorly control diabetes , poorly control congestive heart failure and/or deficiency ) , consider relevant investigator Venous status render impossible place i.v . access Contraindications MRI lumbar puncture Not able understand comply protocol requirement , instruction , protocolstated restriction Unwilling provide inform consent . Exceptions patient physically able provide write informed consent ( e.g . legal representative , consent via voce witness )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>